BFRIW Biofrontera Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001858685
AI RATING
SELL
85% Confidence

Investment Thesis

Biofrontera demonstrates deteriorating fundamental health despite modest revenue growth. Severe cash burn of $13.4M annually combined with negative profitability across all metrics suggests the company is consuming capital at an unsustainable rate. With only $6.4M in cash and negative operating cash flow, the company faces significant liquidity pressure without a clear path to profitability.

Strengths

  • + Revenue growth of 11.7% year-over-year shows top-line expansion
  • + Positive cash position of $6.4M provides some operational runway
  • + Low leverage with 0.00x debt-to-equity ratio reduces financial stress

Risks

  • ! Severe cash burn of $13.4M annually with only 5.7 months of runway at current burn rate
  • ! Consistently negative profitability with -25.3% net margin and -27.2% operating margin
  • ! Operating cash flow of -$13.4M indicates core business cannot fund operations
  • ! Negative ROE of -100.5% and ROA of -36.9% demonstrate capital destruction
  • ! Free cash flow margin of -32.0% indicates value destruction on every dollar of revenue

Key Metrics to Watch

Financial Metrics

Revenue
41.7M
Net Income
-10.5M
EPS (Diluted)
$-1.04
Free Cash Flow
-13.4M
Total Assets
28.6M
Cash
6.4M

Profitability Ratios

Gross Margin N/A
Operating Margin -27.2%
Net Margin -25.3%
ROE -100.5%
ROA -36.9%
FCF Margin -32.0%

Balance Sheet & Liquidity

Current Ratio
1.52x
Quick Ratio
1.40x
Debt/Equity
0.00x
Debt/Assets
63.3%
Interest Coverage
-5.56x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-20T23:12:10.391817 | Data as of: 2025-12-31 | Powered by Claude AI